Pages that link to "Q27678258"

The following pages link to Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product Complex (Q27678258):

Displaying 26 items.

• A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA (Q27339306) (← links)
• An ordered water channel in Staphylococcus aureus FabI: unraveling the mechanism of substrate recognition and reduction. (Q27339591) (← links)
• Structural Basis for the Recognition of Mycolic Acid Precursors by KasA, a Condensing Enzyme and Drug Target from Mycobacterium Tuberculosis (Q27680210) (← links)
• Crystal structures and kinetic properties of enoyl-acyl carrier protein reductase I fromCandidatus Liberibacter asiaticus (Q27681261) (← links)
• A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA. (Q27681724) (← links)
• Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor (Q27683440) (← links)
• Slow-Onset Inhibition of Mycobacterium tuberculosis InhA: Revealing Molecular Determinants of Residence Time by MD Simulations (Q28547385) (← links)
• Understanding ligand-receptor non-covalent binding kinetics using molecular modeling. (Q33796500) (← links)
• Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus (Q34622399) (← links)
• Homologous ligands accommodated by discrete conformations of a buried cavity (Q35549133) (← links)
• Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression. (Q35618052) (← links)
• Analysis of Enoyl-Acyl Carrier Protein Reductase Structure and Interactions Yields an Efficient Virtual Screening Approach and Suggests a Potential Allosteric Site. (Q35741705) (← links)
• Translating slow-binding inhibition kinetics into cellular and in vivo effects (Q35954896) (← links)
• Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors (Q36247329) (← links)
• Asparagine deprivation mediated by Salmonella asparaginase causes suppression of activation-induced T cell metabolic reprogramming. (Q36477909) (← links)
• Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase. (Q36951981) (← links)
• Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). (Q37404976) (← links)
• Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase (Q40322173) (← links)
• Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus (Q40334483) (← links)
• Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase (Q40567992) (← links)
• Characterization of FabG and FabI of the Streptomyces coelicolor dissociated fatty acid synthase (Q41462951) (← links)
• A [(32)P]NAD(+)-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors (Q42732595) (← links)
• Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). (Q47626141) (← links)
• Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics (Q62649644) (← links)
• Kinetic Analyses of the Siderophore Biosynthesis Inhibitor Salicyl-AMS and Analogues as MbtA Inhibitors and Antimycobacterial Agents (Q90737097) (← links)
• Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence (Q91031715) (← links)